Novacyt (AIM: NCYT) has launched its IVDR-certified Yourgene® Insight DPYD assay across regulated European markets, expanding the company’s clinical genetics portfolio.
Novacyt S.A. (AIM: NCYT) Launch of Yourgene® Insight DPYD assay
Paris, France and Manchester, UK – 19 May 2026 – Novacyt S.A. (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international molecular diagnostics company with a broad portfolio of integrated technologies and services, announces
Novacyt S.A. (AIM:NCYT) Full year trading update
Paris, France, and Manchester, UK – 30 January 2025 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international molecular diagnostics company with a broad portfolio of integrated technologies and services, announces an unaudited full year
Novacyt S.A. (AIM: NCYT) London Vet Show: Launch of animal multiplex assays
Launch of new animal multiplex assays at London Vet Show Rapid, accurate detection of six gastrointestinal disease-causing pathogens in cats and dogs
Novacyt S.A. (LON:NCYT) Settlement of the dispute with the DHSC
Paris, France, and Eastleigh and Manchester, UK – 11 June 2024 – Novacyt S.A. (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international molecular diagnostics company with a broad portfolio of integrated technologies and services, announces that the
Yourgene Health PLC (YGEN.L) DHSC contract award for COVID Winter surge testing
Third contract awarded under PHE National Microbiology Framework Agreement
Yourgene Health PLC (YGEN.L) Re DHSC contract to support COVID-19 surge testing
Manchester, UK 10 September 2021: Yourgene (AIM: YGEN), a leading international molecular diagnostic group, announces that a Contract Award Notice has been published in relation to its contract with the